Equillium (EQ) Revenue (2023 - 2024)
Equillium (EQ) posted quarterly Revenue of $4.4 million for Q4 2024, down 52.32% year-over-year from $9.2 million in Q1 2024, and down 63.88% quarter-over-quarter from $12.2 million in Q3 2024.
Equillium (EQ) Revenue (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported Revenue for 2 consecutive years, with $4.4 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Revenue fell 52.32% year-over-year to $4.4 million; the TTM figure through Sep 2025 stood at $4.4 million (down 90.43% YoY), while the FY2024 annual figure was $41.1 million, up 13.89% from the prior year.
- Revenue eased to $4.4 million in Q4 2024 per EQ's latest filing, from $12.2 million in the prior quarter.
- Across five years, Revenue topped out at $13.9 million in Q2 2024 and bottomed at $4.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 12.16 Mn |
| Jun 30, 2024 | 13.85 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 9.21 Mn |
| Sep 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 9.12 Mn |
| Mar 31, 2023 | 8.88 Mn |